Press Releases

Ligand to Report First Quarter Results on May 11th

SAN DIEGO-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report first quarter 2015 financial results on May 11, 2015. Ligand’s CEO John Higgins, President and COO Matt Foehr and Vice President of Finance & Strategy and CFO Nishan De Silva will host the conference call.

First Quarter Earnings Call
 
What:   Ligand conference call to discuss financial results and provide general business updates
 
When: Monday, May 11, 2015
 
Time: 6:00 a.m. Pacific time (9:00 a.m. Eastern time)
 
Webcast:

Conference call and replay accessible at www.ligand.com

 
Conference Call: (877) 407-4019 within the U.S.
(201) 689-8337 outside the U.S.
Passcode: Ligand
 
Replay: (877) 660-6853 within the U.S.
(201) 612-7415 outside the U.S.
Passcode: 13608254

About Ligand Pharmaceuticals

Ligand is a biopharmaceutical company with a business model focused on developing or acquiring royalty generating assets and coupling them with a lean corporate cost structure. Ligand’s goal is to produce a bottom line that supports a sustainably profitable business. By diversifying the portfolio of assets across numerous technology types, therapeutic areas, drug targets and industry partners, we offer investors an opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. In comparison to its peers, we believe Ligand has assembled one of the largest and most diversified asset portfolios in the industry with the potential to generate revenue in the future. These therapies seek to address the unmet medical needs of patients for a broad spectrum of diseases including diabetes, hepatitis, muscle wasting, Alzheimer’s disease, dyslipidemia, anemia, asthma and osteoporosis. Ligand’s Captisol platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances with the world's leading pharmaceutical companies including Novartis, Amgen Inc., Merck, Pfizer, Baxter International and Eli Lilly & Co. Please visit www.captisol.com for more information on Captisol and www.ligand.com for more information on Ligand.

Follow Ligand on Twitter @Ligand_LGND.

Ligand Pharmaceuticals Incorporated
John Higgins, CEO
(858) 550-7500
investors@ligand.com
@Ligand_LGND
or
LHA
Bruce Voss
(310) 691-7100
bvoss@lhai.com
@LHA_IR_PR

Source: Ligand Pharmaceuticals Incorporated